Grass City 20% OFF

HENDERSON, NV / ACCESSWIRE / September 26, 2018 / Two of the most visible sectors on the market recently have been Medical Cannabis and Biotech, respectively. The demonstrated frequency of innovative breakthroughs which are showing to bolster a company’s intrinsic value make equities in the sector appealing to savvy investors and traders alike.

A very interesting biotech firm DCTH (Delcath Systems, Inc.), has an intriguing treatment for liver cancer. The company has initiated a global Phase 3 clinical trial for patients with intrahepatic cholangiocarcinoma (ICC), using its drug product Melphalan/HDS. CTH has commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and has initiated a Registration trial called The ALIGN Trial for intrahepatic cholangiocarcinoma (ICC). If this is the first time you are hearing about DCTH, start doing your own due diligence right away. DCTH is far along in its trial phases as a biotechnology company, and DCTH seems to be very undervalued. DCTH is starting to receive increased attention from the street. Those that Discover DCTH before the public at large, and before the company’s phase 3 clinical trial results could be in store to witness a massive uptrend.

It is rare to find a biotech this far along in its trial phases without much fanfare. This undervalued and unsung hero is starting to become more visible as more investors are beginning to learn about this intriguing story.

Do your due diligence on DCTH now before it’s too late.

Our stocks to watch include: Delcath Systems, Inc. (DCTH), INSYS Therapeutics, Inc. (INSY), Aurora Cannabis (OTCQX:ACBFF), Aphria, Inc. (OTCQB:APHQF), and GW Pharmaceuticals plc (NASDAQ:GWPH).

Delcath Systems, Inc. (DCTH)

Market Cap: $3.337M Share Price: $3.58

Delcath Systems, Inc. (DCTH) was in the news this week announcing data from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, was presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting.

Commenting on the study, Jennifer K. Simpson, PhD, MSN, CRNP, President & CEO of Delcath Systems, said, “Though the cohort in this study was small, the results are consistent with the positive signals provided by other studies published or presented over the last year. The high objective response rate and disease control rate observed in this study is particularly encouraging, as these data points are now the primary and secondary endpoints, respectively, for our amended Registration trial in ocular melanoma liver metastases. As the study authors note, the role of secondary surgery following PHP treatment is currently unclear given the small sample size, but we believe points to the promise this therapy may have for appropriately selected patients.”

The CIRSE 2018 annual meeting is being held in Lisbon, Portugal September 22-25, 2018.

INSYS Therapeutics, Inc. (INSY),

Market Cap: $700.87M Share Price: $9.44

INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently completed a human proof-of-concept study of dronabinol inhalation using a novel and patented breath-actuated device licensed exclusively from U.K.-based Senzer Ltd.

Aurora Cannabis (ACBFF)

Market Cap: $8.87B Share Price: $9.46

Micron Waste Technologies Inc. reported positive results from the optimization of the Cannavore? cannabis waste processing units with Aurora Cannabis Inc.. The Company will now optimize the technology for sub-zero operations, as well as add computerized remote operating capabilities, following which Micron will commence to offer the units commercially.

Aphria, Inc. (APHQF)

Market Cap: $3.53B Share Price: $15.40

Aphria (APHQF) reported that it had signed supply agreements to provide cannabis products with all ten provinces in Canada and the Yukon territory. The company’s depth of supply agreements gives further stability and diversity to the company’s revenue.

GW Pharmaceuticals (GWPH)

Market Cap: $4.69B Share Price: $166.52

GW Pharmaceuticals (GWPH) is on the cusp of shaking up the U.S. epilepsy treatment market. The medical marijuana company won FDA approval for Epidiolex’s use in rare childhood-onset epilepsy over the summer and it should become commercially available to patients as soon as a decision is made on scheduling it by the Drug Enforcement Agency.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eight thousand dollars total by Regal Consulting. LLC, for news commentary articles for DCTH. DCTH and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of DCTH in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC.For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States


SOURCE: ACR Communication, LLC